Granulocyte colony-stimulating factor induces sensorimotor recovery in intracerebral hemorrhage

Brain Res. 2005 Apr 18;1041(2):125-31. doi: 10.1016/j.brainres.2004.11.067.

Abstract

Granulocyte colony-stimulating factor (G-CSF) has been used in the treatment of neutropenia in hematologic disorders. The neuroprotective and anti-inflammatory effects of G-CSF were reported in various neurological disease models. In this study, we examined whether G-CSF induces functional recovery after intracerebral hemorrhage (ICH). ICH was induced using collagenase injection in adult rats. Either G-CSF (50 microg/kg, i.p.) or saline was given from 2 h after ICH and every 24 h for 3 days. 72 h after ICH induction, the rats were sacrificed for histological analysis and measurement of brain edema. Behavioral tests were performed before and 1, 7, 14, 21, 28, and 35 days after ICH. We also measured the blood-brain barrier (BBB) permeability using Evans blue dye injection method. G-CSF-treated rats recovered better on rotarod and limb placing tests, starting from 14 days throughout 5 weeks after ICH. The brain water content and BBB permeability of G-CSF-treated group decreased in the lesioned hemispheres compared with those of ICH-only group. In G-CSF-treated group, the number of TUNEL+, myeloperoxidase+, and OX42+ cells was smaller than that of ICH-only group in the periphery of hematoma. These findings suggest that G-CSF induces long-term sensorimotor recovery after ICH with reduction of brain edema, inflammation, and perihematomal cell death.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atrophy / drug therapy
  • Atrophy / etiology
  • Atrophy / physiopathology
  • Biomarkers / metabolism
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / physiopathology
  • Brain Edema / drug therapy
  • Brain Edema / etiology
  • Brain Edema / physiopathology
  • Cerebral Hemorrhage / complications
  • Cerebral Hemorrhage / drug therapy*
  • Cerebral Hemorrhage / physiopathology
  • Collagenases
  • Disease Models, Animal
  • Encephalitis / drug therapy
  • Encephalitis / etiology
  • Encephalitis / physiopathology
  • Evans Blue
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Male
  • Motor Activity / drug effects
  • Motor Activity / physiology
  • Movement Disorders / drug therapy*
  • Movement Disorders / etiology
  • Movement Disorders / physiopathology
  • Nerve Degeneration / drug therapy
  • Nerve Degeneration / etiology
  • Nerve Degeneration / physiopathology
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use
  • Rats
  • Rats, Sprague-Dawley
  • Recovery of Function / drug effects*
  • Recovery of Function / physiology
  • Sensation Disorders / drug therapy*
  • Sensation Disorders / etiology
  • Sensation Disorders / physiopathology
  • Treatment Outcome

Substances

  • Biomarkers
  • Neuroprotective Agents
  • Granulocyte Colony-Stimulating Factor
  • Evans Blue
  • Collagenases